Breast cancer remains the most common cause of cancer mortality amongst females in western society. Metastatic disease develops in 30-40% of patients and treatment strategies continue to seek management regimens that will allow an increased quality and quantity of survival.
Xeloda (capcitabine), an oral fluoropyrimidinecarbamate, was designed to generate 5-Fluorouracil (5-FU) directly within the tumour cell, thus minimising the systemic exposure and subsequent gastrointestinal toxicities seen with intravenous 5-FU. The oral formulation allows for a convenient delivery of therapy, which can be given outside the hospital or clinic setting.
Click on the link above to read the attached report by Associate Professor Michael Green.